These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 15726418)

  • 21. BRCA1/2 in high-risk African American women with breast cancer: providing genetic testing through various recruitment strategies.
    Pal T; Vadaparampil S; Betts J; Miree C; Li S; Narod SA
    Genet Test; 2008 Sep; 12(3):401-7. PubMed ID: 18752448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India.
    Saxena S; Chakraborty A; Kaushal M; Kotwal S; Bhatanager D; Mohil RS; Chintamani C; Aggarwal AK; Sharma VK; Sharma PC; Lenoir G; Goldgar DE; Szabo CI
    BMC Med Genet; 2006 Oct; 7():75. PubMed ID: 17018160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2.
    Schubert EL; Lee MK; Mefford HC; Argonza RH; Morrow JE; Hull J; Dann JL; King MC
    Am J Hum Genet; 1997 May; 60(5):1031-40. PubMed ID: 9150150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort.
    Haiman CA; Garcia RR; Hsu C; Xia L; Ha H; Sheng X; Le Marchand L; Kolonel LN; Henderson BE; Stallcup MR; Greene GL; Press MF
    BMC Cancer; 2009 Jan; 9():43. PubMed ID: 19183483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
    Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Kwan E; Jack E; Vesprini DJ; Kuperstein G; Abrahamson JL; Fan I; Wong B; Narod SA
    Am J Hum Genet; 2001 Mar; 68(3):700-10. PubMed ID: 11179017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A haplotype-based case-control study of BRCA1 and sporadic breast cancer risk.
    Freedman ML; Penney KL; Stram DO; Riley S; McKean-Cowdin R; Le Marchand L; Altshuler D; Haiman CA
    Cancer Res; 2005 Aug; 65(16):7516-22. PubMed ID: 16103107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRCA1 and BRCA2 germline mutations in Moroccan breast/ovarian cancer families: novel mutations and unclassified variants.
    Tazzite A; Jouhadi H; Nadifi S; Aretini P; Falaschi E; Collavoli A; Benider A; Caligo MA
    Gynecol Oncol; 2012 Jun; 125(3):687-92. PubMed ID: 22425665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.
    Meindl A;
    Int J Cancer; 2002 Feb; 97(4):472-80. PubMed ID: 11802209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk.
    Pelletier C; Speed WC; Paranjape T; Keane K; Blitzblau R; Hollestelle A; Safavi K; van den Ouweland A; Zelterman D; Slack FJ; Kidd KK; Weidhaas JB
    Cell Cycle; 2011 Jan; 10(1):90-9. PubMed ID: 21191178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
    Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
    J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Germline mutation of BRCA1 gene in Polish families with strong aggregation of breast and/or ovarian cancer based on coding sequence analysis using the SSCP method].
    Byrski T
    Ann Acad Med Stetin; 2003; 49():27-43. PubMed ID: 15552838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families.
    Vallon-Christersson J; Cayanan C; Haraldsson K; Loman N; Bergthorsson JT; Brøndum-Nielsen K; Gerdes AM; Møller P; Kristoffersson U; Olsson H; Borg A; Monteiro AN
    Hum Mol Genet; 2001 Feb; 10(4):353-60. PubMed ID: 11157798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
    Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
    Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States.
    Huo D; Senie RT; Daly M; Buys SS; Cummings S; Ogutha J; Hope K; Olopade OI
    J Clin Oncol; 2009 Mar; 27(8):1184-90. PubMed ID: 19188678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Awareness and preferences regarding BRCA1/2 genetic counseling and testing among Latinas and non-Latina white women at increased risk for hereditary breast and ovarian cancer.
    Gammon AD; Rothwell E; Simmons R; Lowery JT; Ballinger L; Hill DA; Boucher KM; Kinney AY
    J Genet Couns; 2011 Dec; 20(6):625-38. PubMed ID: 21691939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: identification of four novel mutations and high-frequency occurrence of 185delAG mutation.
    Vaidyanathan K; Lakhotia S; Ravishankar HM; Tabassum U; Mukherjee G; Somasundaram K
    J Biosci; 2009 Sep; 34(3):415-22. PubMed ID: 19805903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area.
    Pohlreich P; Zikan M; Stribrna J; Kleibl Z; Janatova M; Kotlas J; Zidovska J; Novotny J; Petruzelka L; Szabo C; Matous B
    Breast Cancer Res; 2005; 7(5):R728-36. PubMed ID: 16168118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast-ovarian cancer families. Identification of novel mutations and unclassified variants.
    Delgado L; Fernández G; Grotiuz G; Cataldi S; González A; Lluveras N; Heguaburu M; Fresco R; Lens D; Sabini G; Muse IM
    Breast Cancer Res Treat; 2011 Jul; 128(1):211-8. PubMed ID: 21190077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry.
    Kurian AW; Gong GD; John EM; Miron A; Felberg A; Phipps AI; West DW; Whittemore AS
    Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1084-91. PubMed ID: 19336551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequency and spectrum of mutations across 94 cancer predisposition genes in African American women with invasive breast cancer.
    Lovejoy LA; Rummel SK; Turner CE; Shriver CD; Ellsworth RE
    Fam Cancer; 2021 Jul; 20(3):181-187. PubMed ID: 33083949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.